secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2026-06-08T20:03:16+00:00
Accession:  0001185185-26-002410
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC Pharma extends $12M loan agreement with O-Bank; facility fee rises to $60,000
--------------------------------------------------------------------------------

- Entered amendment to extend Master Loan and Security Agreement with O-Bank Co., Ltd.
- Facility maximum aggregate limit remains $12,000,000 unchanged from 2025.
- Facility fee increased from $48,000 to $60,000; other terms substantially unchanged.
- Loan agreement continues the general banking facility arrangement originally dated June 24, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/0001185185-26-002410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/igc8k060826.htm
  HTML page:      https://secwatch.observer/filing/0001185185-26-002410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer